Rockefeller Capital Management L.P. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 20.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 719 shares of the medical research company's stock after acquiring an additional 124 shares during the quarter. Rockefeller Capital Management L.P.'s holdings in Bio-Rad Laboratories were worth $299,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the company. Sentry Investment Management LLC grew its holdings in Bio-Rad Laboratories by 16.5% in the second quarter. Sentry Investment Management LLC now owns 148 shares of the medical research company's stock valued at $73,000 after purchasing an additional 21 shares during the last quarter. Arizona State Retirement System grew its holdings in Bio-Rad Laboratories by 0.4% in the second quarter. Arizona State Retirement System now owns 6,245 shares of the medical research company's stock valued at $3,091,000 after purchasing an additional 23 shares during the last quarter. Mather Group LLC. grew its holdings in Bio-Rad Laboratories by 6.8% in the first quarter. Mather Group LLC. now owns 377 shares of the medical research company's stock valued at $212,000 after purchasing an additional 24 shares during the last quarter. Kestra Private Wealth Services LLC grew its holdings in Bio-Rad Laboratories by 3.2% in the second quarter. Kestra Private Wealth Services LLC now owns 809 shares of the medical research company's stock valued at $400,000 after purchasing an additional 25 shares during the last quarter. Finally, Raymond James Trust N.A. grew its holdings in Bio-Rad Laboratories by 5.5% in the first quarter. Raymond James Trust N.A. now owns 501 shares of the medical research company's stock valued at $283,000 after purchasing an additional 26 shares during the last quarter. Institutional investors and hedge funds own 64.35% of the company's stock.
Get
Bio-Rad Laboratories alerts:
Bio-Rad Laboratories Stock Up 0.7 %
Shares of NYSE:BIO opened at $467.46 on Wednesday. The stock's 50-day moving average price is $428.58 and its two-hundred day moving average price is $446.98. The company has a current ratio of 5.50, a quick ratio of 4.30 and a debt-to-equity ratio of 0.14. Bio-Rad Laboratories, Inc. has a 12-month low of $344.63 and a 12-month high of $670.61. The firm has a market cap of $13.94 billion, a price-to-earnings ratio of -2.32 and a beta of 0.91.
Analyst Upgrades and Downgrades
Several analysts have weighed in on BIO shares. TheStreet lowered Bio-Rad Laboratories from a "c" rating to a "d+" rating in a report on Thursday, October 27th. Royal Bank of Canada began coverage on Bio-Rad Laboratories in a research note on Tuesday, December 6th. They set an "outperform" rating and a $565.00 price objective on the stock. StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, January 18th. Finally, Credit Suisse Group decreased their price objective on Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating on the stock in a research note on Friday, October 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $651.25.
Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Recommended Stories
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
